Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn's disease
2005-002319-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AZD9056 200 mg once daily with Placebo once daily (2 arms). Started Oct 2005; status: completed.
02
Drugs
AZD9056
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2005-002319-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002319-26.